Aclaris Therapeutics, Inc. (ACRS) SEC Filings & Earnings Calls

Clinical-stage biotech with no approved products, net losses

“Net loss was $21.5 million for the second quarter of 2026” · word for word

Dilution from ATM share sales

“sold 7.3 million shares of its common stock for aggregate gross proceeds of $40.2 million” · word for word

Clinical-stage biotech with no approved products and history of losses

“Since inception, the Company has incurred net losses and negative cash flows from its operations.” · word for word

Dependence on future capital raises for continued operations

“The Company will require additional capital to develop its product candidates and to support its discovery efforts.” · word for word

Concentration of revenue from a few licensing partners

“The Company recognized $1.1 million and $1.3 million of licensing revenue during the three months ended June 30, 2026 and 2025, respectively, all of which was payable to third parties.”

Potential dilution from future equity sales; no immediate obligation to sell.

“Company may offer and sell shares from time to time at its sole discretion.”

Clinical trial failure risk for pipeline assets ATI-052 and bosakitug; results expected H2 2026.

“Top line results from Phase 1b POC trials of ATI-052 and Phase 2 trial of bosakitug expected in second half of 2026.”

Cash burn rate increased; net loss widened 31% YoY.

“Net loss $19.8M vs $15.1M; R&D spend up 35%.”

Clinical-stage biotech with no approved products and history of losses

“Since inception, the Company has incurred net losses and negative cash flows from its operations.” · word for word

Dependence on future capital raises for continued operations

“The Company will require additional capital to develop its product candidates and to support its discovery efforts.” · word for word

Concentration of revenue from a few licensing partners

“The Company recognized $1.3 million and $1.0 million of licensing revenue during the three months ended March 31, 2026 and 2025, respectively, all of which was payable to third parties.”

Clinical and regulatory risks inherent in drug development; no revenue-generating products yet

“Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the conduct of clinical trials, Aclaris’ reliance on third parties over which it may not always have full control, Aclaris’ ability to enter into strategic partnerships on commercially reasonable terms” · word for word

Dilution risk from equity offering; potential signal of cash burn.

“sold 5.7 million shares of its common stock, for aggregate gross proceeds of $20.0 million” · word for word

Dilutive equity offering signals ongoing cash needs; potential for further dilution.

“sold 12.7 million shares of its common stock, for aggregate gross proceeds of $39.8 million” · word for word

Clinical-Stage Biotech Cash Burn

“We have incurred significant losses since our inception. We expect to incur losses over the next several years and may never achieve or maintain profitability.” · word for word

China Supply Chain Dependency

“We currently use manufacturers in China to manufacture certain product candidates for use in our clinical trials. For example, we currently rely on WuXi Biologics (Hong Kong) Limited ('WuXi Biologics') for the production of product necessary to complete our upcoming clinical trial for bosakitug.”

AI Competition Risk

“Competitors using AI may identify superior kinase inhibitors targeting the same pathways we are pursuing; AI-enabled clinical trial design and patient selection may allow competitors to achieve proof-of-concept more rapidly and efficiently.” · word for word

Clinical trial failure risk for pipeline candidates

“Phase 1b and Phase 2 trials ongoing; no approved products.”

Revenue dependency on license milestones

“Revenue decreased significantly due to milestone timing; no product revenue.”

Cash burn rate may require future financing

“Cash decreased from $203.9M to $151.4M; R&D expenses increasing.”

Early-stage clinical data; further trials needed to confirm efficacy and safety.

“Phase 1a interim results; Phase 1b and Phase 2b trials planned for asthma and atopic dermatitis.”

Going concern risk due to ongoing losses

“Since inception, the Company has incurred net losses and negative cash flows from its operations.” · word for word

Dependence on partnership/licensing revenue

“Revenue is heavily dependent on licensing agreements with Lilly, Sun Pharma, and others.”

Clinical trial failure risk

“The Company is a clinical-stage biopharmaceutical company focused on developing novel product candidates.” · word for word

Capital needs risk

“The Company will require additional capital to develop its product candidates and to support its discovery efforts.” · word for word

Clinical-stage biotech with no approved products; pipeline risk.

“Company is clinical-stage; no approved products; pipeline dependent on trial outcomes.”

Net loss increased YoY; cash burn continues.

“Net loss $14.6M vs $7.6M prior year; cash decreased from $203.9M to $167.2M.”